AVBP Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
52.7M
+14.3%
46.1M
+18.8%
38.8M
+1.3%
38.3M
+14.0%
33.6M
R&D
42.3M
+12.6%
37.6M
+16.9%
32.2M
+0.0%
32.2M
+16.0%
27.7M
SG&A
10.4M
+21.9%
8.5M
+27.8%
6.6M
+8.1%
6.1M
+4.2%
5.9M
Operating Income
-52691000
-14.3%
-46111000
-18.8%
-38823000
-1.3%
-38316000
-14.0%
-33623000
EBITDA
-52691000
-12.9%
-46670000
-11.5%
-41849000
-9.2%
-38316000
-14.0%
-33623000
Net Income
-49893000
-15.2%
-43320000
-21.9%
-35544000
-1.6%
-34978000
-11.4%
-31399000
EPS (Basic)
$-1.05
-9.4%
$-0.96
-15.7%
$-0.83
+0.0%
$-0.83
+7.8%
$-0.90
EPS (Diluted)
$-1.05
-9.4%
$-0.96
-15.7%
$-0.83
+0.0%
$-0.83
+7.8%
$-0.90
Shares (Diluted)
47.6M
+5.6%
45.1M
+4.7%
43.0M
+2.7%
41.9M
+19.7%
35.0M
ArriVent BioPharma (AVBP) โ€” Financials